Details

Industry: Industrial Markets, Chemicals, Biotechnology & Pharmaceuticals
Type: White paper
Date: 6/12/2009

Global M&A: Outlook for Pharmaceuticals 2009

The pharmaceuticals and biotechnology sectors are currently battling with declining pipelines, patent expirations and a clampdown on healthcare spending. As their troubles grow, the sectors are being forced to increasingly engage in mergers and acquisitions (M&A) activity. KPMG's study examines the outlook for M&A.

Download Now

Global MA - Pharmaceuticals.pdf

PDF files require Adobe Reader to view

Download Adobe Reader

The pharmaceuticals and biotechnology sectors are currently battling with declining pipelines, patent expirations, and a clampdown on healthcare spending. As their troubles grow, the sectors are being forced to increasingly engage in mergers and acquisitions (M&A) activity.

This August 2009 edition of Global M&A attempts to provide insight into the following topics:

Global M&A review: The return of megamergers
Americas dominate regional activity
Analysis by sector
Analysis by acquirer type: Cash-rich pharma goes on a buying spree
Key deals in 2009
Outlook: The path ahead – Megamergers or smaller strategic deals?

© 2012 KPMG LLP, a Canadian limited liability partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. All rights reserved.

KPMG International Cooperative ("KPMG International") is a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.

KPMG On-Line Privacy Policy